Gender
All
Age Group
18 Years and up
Accepting Healthy Volunteers
No
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically/cytologically confirmed diagnosis of previously untreated and
pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung
cancer (NSCLC) [American Joint Committee on Cancer (AJCC) 8th Edition]
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within
7 days before the first dose of study intervention
- Participants who have not achieved a pathological complete response (pCR) following
completion of neoadjuvant chemotherapy and pembrolizumab followed by surgery will be
eligible
- Confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not
indicated as primary therapy (documentation of absence of tumor-activating EGFR
mutations [eg, DEL19 or L858R])
- Human immunodeficiency virus (HIV)-infected participants must have well controlled
HIV on anti-retroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if
they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks
and have undetectable HBV viral load prior to randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV
viral load is undetectable at screening
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Diagnosis of SCLC or, for mixed tumors, presence of small cell elements, or has a
neuroendocrine tumor with large-cell components, or a sarcomatoid carcinoma, or a
pancoast tumor
- Documentation by local test report indicating presence of anaplastic lymphoma kinase
(ALK) gene rearrangements
- Received prior neoadjuvant therapy for their current NSCLC diagnosis
- Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed
cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent,
or with an agent directed to another stimulatory or coinhibitory T-cell receptor
(eg, cytotoxic T-lymphocyte-associated protein [CTLA-4], OX-40, CD137)
- Received prior systemic anticancer therapy including investigational agents other
than what is specified in this protocol
- Received prior treatment with a cancer vaccine
- Received prior radiotherapy within 2 weeks of start of study intervention, or has
radiation-related toxicities, requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of
study intervention